How do you manage steroid-refractory acute GVHD following allogeneic transplant?
What criteria do you use to define steroid-refractory disease?
Does your management different by organ system involved - GI vs skin vs other?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Maryland Cancer Center
Answered on
The short answer is to enroll the patient in a well-designed clinical trial, if available.
If not, I would start with ruxolitinib based on the REACH2 trial (Zeiser et al., PMID 32320566) which was multicenter, randomized, open-label, phase 3 trial comparing the efficacy and safety of oral ruxolitini...
Join for free or sign in to see the full answer